To our Valued Patients, Customers and Health Care providers, As we navigate through these trying times surrounding the Coronavirus (COVID-19)...
Read More
Painless, Non-Invasive Skin Cancer Therapy
Learn MoreBringing back Quality of Life
Need an Appointment?
Has COVID-19 changed or postponed your Skin Cancer treatment date?
With the Rhenium-SCT Referral Program we connect you with the nearest treatment center.
Rhenium-SCT Referral Program:
request the next possible treatment date here.
Rhenium-SCT®
The Rhenium-SCT (Skin Cancer Therapy) is a specialized state-of-the-art brachytherapy utilizing the radioisotope Rhenium-188, a beta-emitter which in this case is used for the treatment of basal and squamous cell carcinomas of the skin.
Further Information
188W/188Re Generator
Production of high-energy beta emitting 188Re
Various sizes available
up to 150GBq (4Ci) 188W
High activity concentration
up to 9GBq/ml
Variable elution volume
Elution volume of 5-14 ml (partial elution for small volumes)
Low breakthrough
188W < 0.01 % in relation to 188Re at calibration time
Recent Events
OncoBeta GmbH and Australian Nuclear Science and Technology Organisation sign Letter of Intent to establish manufacturing site in Australia
By Mireya Torres
/ September 24, 2020
Innovative medical device Rhenium-SCT therapy for Non-Melanoma Skin Cancer to be produced in Australia
Read More
Group RPH and OncoBeta GmbH sign agreement for Sales Referral and Distribution of Rhenium-SCT® in Brazil.
By darksy
/ September 10, 2020
Grupo RPH is now the Official Rhenium-SCT® Sales Representative and Distributor in Brazil for the treatment of Non-Melanoma Skin Cancer.
Read More
Personalized irradiation therapy for NMSC by rhenium-188 skin cancer therapy: a long-term retrospective study
By Mireya Torres
/ July 13, 2020
Abstract Objectives This study aimed to provide long-term clinical data about an innovative epidermal radioisotope therapy called Rhenium-SCT® (Skin Cancer...
Read More
China Isotope & Radiation Corporation (CIRC) and OncoBeta sign distribution agreement for Tungsten 188/Rhenium-188 generators
By darksy
/ June 30, 2020
Beijing, China and Garching near Munich, Germany, Tuesday 30th June 2020. CIRC and OncoBeta today announced that they have signed an agreement for the distribution of high energy beta particle W/Re-188 generators in China.
Read More
How can you Reduce the Risk of Skin Cancer?
By darksy
/ June 2, 2020
Skin Cancer is the most common type of cancer in the world 1. Ultraviolet (UV) Radiation exposure is one of...
Read More
B.J. Madan & Co India and OncoBeta announce exclusive distribution agreement for W/Re-188 generators.
By darksy
/ March 6, 2020
New Delhi, India and Garching near Munich, Germany, 6th March, 2020. B.J Madan & Co and OncoBeta announced the execution...
Read More
RadioMedix and OncoBeta announce exclusive distribution agreement for W/Re-188 generators in U.S. and Canada.
By darksy
/ February 7, 2020
RadioMedix and OncoBeta today announced the execution of an exclusive distribution agreement for the next generation of W/Re-188 generators in the U.S. and Canada.
Read More
Oncobeta chosen as one of the Trailblazing Companies to Watch in 2019
By darksy
/ December 23, 2019
OncoBeta- A Pioneer And Innovator In The Epidermal Radioisotope Therapy Sector Skin is the largest organ of the body and...
Read More
OncoBeta® receives Corporate Excellence Award 2019
By darksy
/ December 10, 2019
OncoBeta recognized as the Most Compassionate Skin Cancer Therapy Provider in 2019.
OncoBeta®, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), has recently been presented with the CV Magazine’s Corporate Excellence Award for the Most Compassionate Skin Cancer Therapy Provider in 2019.
Read More